Akums Drugs, a company in the Pharmaceuticals industry, reported revenue of ₹1,342 crore and net profit of ₹115 crore for the September 2026 quarter.
Akums Drugs (NSE: AKUMS) closed at ₹696.20 on 20 Nov 2026, up 65.2% over the past year. Its market capitalisation is ₹10,958 crore and it trades at 29.1 times earnings.
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.